These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 17662104

  • 1. Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha.
    Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B, Berg T.
    Am J Gastroenterol; 2007 Dec; 102(12):2724-31. PubMed ID: 17662104
    [Abstract] [Full Text] [Related]

  • 2. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M, Hernàndez J, Arenas MD, Carnicer F, Caramelo C, Fabrizi F.
    Kidney Blood Press Res; 2015 Dec; 40(3):258-65. PubMed ID: 25997572
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N, Mehtap O, Gümrah M, Arican N.
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [Abstract] [Full Text] [Related]

  • 4. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
    Kohjima M, Yoshimoto T, Enjoji M, Fukushima N, Fukuizumi K, Nakamura T, Kurokawa M, Fujimori N, Sasaki Y, Shimonaka Y, Murata Y, Koyama S, Kawabe K, Haraguchi K, Sumida Y, Harada N, Kato M, Kotoh K, Nakamuta M.
    World J Gastroenterol; 2015 Mar 21; 21(11):3291-9. PubMed ID: 25805936
    [Abstract] [Full Text] [Related]

  • 5. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G.
    Neth J Med; 2008 May 21; 66(5):191-5. PubMed ID: 18490796
    [Abstract] [Full Text] [Related]

  • 6. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.
    J Gastroenterol Hepatol; 2008 Jun 21; 23(6):861-6. PubMed ID: 18422960
    [Abstract] [Full Text] [Related]

  • 7. Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.
    Brochot E, Riachi G, Plantier JC, Guillemard C, Vabret A, Mathurin P, Nguyen-Khac E, Duverlie G, G4 group.
    J Med Virol; 2013 Jul 21; 85(7):1191-8. PubMed ID: 23918537
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, Thibault V, Souberbielle JC, Carrat F, Cacoub P.
    World J Gastroenterol; 2015 May 14; 21(18):5647-53. PubMed ID: 25987791
    [Abstract] [Full Text] [Related]

  • 9. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
    Kim CH, Park BD, Lee JW, Kim YS, Jeong S, Lee DH, Kim HG, Shin YW, Kwon KS, Lee JI.
    Korean J Hepatol; 2009 Mar 14; 15(1):70-9. PubMed ID: 19346787
    [Abstract] [Full Text] [Related]

  • 10. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
    J Viral Hepat; 2007 Oct 14; 14(10):721-9. PubMed ID: 17875007
    [Abstract] [Full Text] [Related]

  • 11. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T.
    Gastroenterology; 2011 Nov 14; 141(5):1656-64. PubMed ID: 21784046
    [Abstract] [Full Text] [Related]

  • 12. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, Yang SS, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Yu ML, Kao JH.
    Ann Intern Med; 2013 Dec 03; 159(11):729-38. PubMed ID: 24297189
    [Abstract] [Full Text] [Related]

  • 13. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
    Lange CM, von Wagner M, Bojunga J, Berg T, Farnik H, Hassler A, Sarrazin C, Herrmann E, Zeuzem S.
    Eur J Gastroenterol Hepatol; 2010 Nov 03; 22(11):1303-7. PubMed ID: 20729742
    [Abstract] [Full Text] [Related]

  • 14. [Clinical observation of Hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy].
    Teng ZL, Gong WJ, Zhang SQ, Sun YX, Ma XH.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Feb 03; 21(2):101-4. PubMed ID: 23663880
    [Abstract] [Full Text] [Related]

  • 15. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C, ANRS HCO2 RIBAVIC Study Team.
    JAMA; 2004 Dec 15; 292(23):2839-48. PubMed ID: 15598915
    [Abstract] [Full Text] [Related]

  • 16. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
    Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S, Vahabpour R, Keyvani H.
    J Med Virol; 2014 Sep 15; 86(9):1499-506. PubMed ID: 24889558
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL.
    J Gastroenterol Hepatol; 2010 Feb 15; 25(2):259-63. PubMed ID: 19817959
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF, Shi KQ, Lin YQ, Wang LR, He JP, Braddock M, Chen YP, Zheng MH.
    Gene; 2014 Jul 10; 544(2):101-6. PubMed ID: 24793583
    [Abstract] [Full Text] [Related]

  • 19. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G, Tolvaj G, Halász T, Stotz G.
    Orv Hetil; 2007 Aug 19; 148(33):1545-50. PubMed ID: 17686672
    [Abstract] [Full Text] [Related]

  • 20. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
    Brost S, Zimmermann A, Koschny R, Sykora J, Stremmel W, Schirmacher P, Walczak H, Ganten TM.
    Pathol Res Pract; 2014 Feb 19; 210(2):83-91. PubMed ID: 24268735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.